Differential activation of JAK enzymes in rheumatoid arthritis and autoimmune disorders by pro-inflammatory cytokines: Potential drug targets

International Journal of Interferon, Cytokine and Mediator Research

Volumn 2, Issue 1, 2010, Pages 97-111

  Malemud, Charles J ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmunity; Cytokines; Inflammation; Janus kinase; Signal transducers and activators of transcription; Small molecule inhibitors

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR ALPHA; JANUS KINASE; METALLOPROTEINASE; PHOSPHATIDYLINOSITOL 3 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CARTILAGE CELL; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CROHN DISEASE; ENZYME ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE INTERACTION; HUMAN; NONHUMAN; OSTEOCLAST; PATHOGENESIS; PHOSPHORYLATION; PSORIASIS; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN LUPUS ERYTHEMATOSUS;

EID: 78649385348     PISSN: None     EISSN: 1179139X     Source Type: Book Series    
DOI: 10.2147/IJICMR.S9470     Document Type: Article

References (227)

1. Ivashkiv LB, Hu X. Signaling by STATs. Arthritis Res Ther. 2004;6(4): 159-168.
2. Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol. 2005;32(9):1650-1653.
3. Murray PJ. The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007;178(5):2623-2629.
4. Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. Curr Rheumatol Rev. 2008;4(4):219-234.
5. Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in rheumatoid arthritis and the new antidepression drugs. Expert Opin Ther Targets. 2008;12(2):171-183.
6. Walker JG, Ahern MJ, Coleman M, et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique Jak3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis. 2006;65(2):149-156.
7. Barton A, Thomson W, Ke X, et al. Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. Hum Mol Genet. 2008;17(15):2274-2279.
8. Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977-986.
9. Imboden JB. The immunopathogenesis of rheumatoid arthritis. Annu Rev Pathol. 2009;4:417-434.
10. Ivashkiv LB. Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity. 2003;36(8):473-479.
11. Glas J, Seiderer J, Nagy M, et al. Evidence for STAT4 as a common autoimmune gene: rs7574865 is associated with colonic Crohn's disease and early disease onset. PLoS One. 2010;5(4):e10373.
12. Hebenstreit D, Horejs-Hoeck J, Duschl A. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect. 2005;18(4): 243-249.
13. Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 2002; 13(4-5):357-368.
14. Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. Open Access Rheumatol Res Rev. 2009;1:133-150.
15. Saini M, Pearson C, Seddon B. Regulation of T cell-dendritic cell interactions by IL-7 governs T-cell activation and homeostasis. Blood. 2009;113(23):5793-5800.
16. Vogt TK, Link A, Perrin J, Finke D, Luther SA. Novel function for interleukin-7 in dendritic cell development. Blood. 2009;113(17): 3961-3968.
17. Churchman SM, Ponchel F. Interleukin-7 in rheumatoid arthritis. Rheumatology (Oxford). 2008;47(6):753-759.
18. Schmutz S, Bosco N, Chappaz S, et al. Cutting edge: IL-7 regulates the peripheral pool of adult ROR γ+ lymphoid tissue inducer cells. J Immunol. 2009;183(4):2217-2221.
19. Malemud CJ. The discovery of novel experimental therapies for inflammatory arthritis. Mediators Inflam. 2009;2009:698769.
20. Cordero OJ, Salgado FJ, Mera-Varela A, Nogueira M. Serum interleukin-12, interleukin-15, soluble CD26, and adenosine deaminase in patients with rheumatoid arthritis. Rheumatol Int. 2001;21(2): 69-74.
21. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3): 1910-1914.
22. 2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23/interleukin-17 axis. Arthritis Rheum. 2007;56(8):2608-2619.
23. Paradowska-Gorycka A, Grzybowska-Kowalczyk A, Wojtecka-Lukasik E, Maslinski S. IL-23 in the pathogenesis of rheumatoid arthritis. Scand J Immunol. 2010;71(3):134-145.
24. Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs. 2003;4(5):572-577.
25. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune inflammation from the Th17 perspective. Autoimmun Rev. 2007;6: 169-175.
26. Sarkar S, Tesmer LA, Hindnavis V, Endres JL, Fox DA. Interleukin-17 as a molecular target in immune-mediated arthritis: immunoregulatory properties of genetically modified murine dendritic cells that secrete interleukin-4. Arthritis Rheum. 2007;56(1):89-100.
27. Toh ML, Kawashima M, Hot A, Miossec P, Miossec P. Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rβ2 inhibition. Ann Rheum Dis. 2010;69(8):1562-1567.
28. Horvath CM. The Jak-STAT pathway stimulated by interferon alpha or interferon beta. Sci STKE. 2004;2004(260):tr10.
29. Schindler C, Plumlee C. Interferons pen the JAK-STAT pathway. Semin Cell Dev Biol. 2008;19(4):311-318.
30. Gough DJ, Levy DE, Johnstone RW, Clarke CJ. IFNγ signaling - does it mean JAK-STAT? Cytokine Growth Factor Rev. 2008;19(5-6): 383-394.
31. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity. 2009;31(4):539-550.
32. + regulatory T cells. J Immunol. 2009;182(11):6736-6743.
33. Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory diseases. Curr Signal Transduct Ther. 2009; 4:201-221.
34. Jongbloed SL, Benson RA, Nickdel MB, Garside P, McInnes IB, Brewer JM. Plasmacytoid dendritic cells regulate breach of self-tolerance in autoimmune arthritis. J Immunol. 2009;182(2):963-968.
35. Sozzani S, Vermi W, Prete AD, Fracchetti F. Trafficking properties of plasmacytoid dendritic cells in health and disease. Trends Immunol. 2010;31(7):270-277.
36. Conigliaro P, Perricone C, Benson RA, et al. The type I IFN system in rheumatoid arthritis. Autoimmunity. 2010;43(3):220-225.
37. + regulatory T cells in health and disease. Clin Exp Pharmacol Physiol. 2006;33(5-6):519-524.
38. + CD25 high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis. Cell Immunol. 2008;253(1-2): 92-101.
39. Boissier MC, Assier E, Biton J, Denys A, Falgarone G, Bessis N. Regulatory T cells (Treg) in rheumatoid arthritis. Joint Bone Spine. 2009;76(1):10-14.
40. Crome SQ, Wang AY, Levings MK. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol. 2010;159(2):109-119.
41. van der Vliet HJ, Nieuwenhuis EE. IPEX as a result of mutations in FOXP3. Clin Dev Immunol. 2007;2007:89017.
42. Bacchetta R, Passerini L, Gambineri E, et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Invest. 2006;116(6):1713-1722.
43. Jiang H, Harris MB, Rothman P. IL-4/IL-13 signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105(6 Pt 1):1063-1070.
44. Donnelly RP, Dickensheets H, Finbloom DS. The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes. J Interferon Cytokine Res. 1999;19(6):563-573.
45. Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. J Recept Signal Transduct Res. 1999;19(1-4):75-120.
46. Spadaro A, Rinaldi T, Riccieri V, Taccari E, Valesini G. Interleukin-13 in autoimmune rheumatic diseases: relationship with autoantibody profile. Clin Exp Rheumatol. 2002;20(2):213-216.
47. Spadaro A, Rinaldi T, Riccieri V, Valesini G, Taccari E. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. Ann Rheum Dis. 2002;61(2):174-176.
48. Lejuene D, Dumoutier L, Constantinescu S, Kruijer W, Schuringa JJ, Renauld JC. Interleukin-22 (IL-22) activates the JAK/STAT, ERK, JNK and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10. J Biol Chem. 2002;277(37):33676-33682.
49. Travagli J, Letourneur M, Bertoglio J, Pierre J. STAT6 and Ets-1 form a stable complex that modulates Socs-1 expression by interleukin-4 in ketatinocytes. J Biol Chem. 2004;279(34):35183-35192.
50. Davey GM, Heath WR, Starr R. SOCS1: a potent and multifaceted regulator of cytokines and cell-mediated inflammation. Tissue Antigens. 2006;67(1):1-9.
51. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28(4):477-487.
52. Tsuji-Takayama K, Suzuki M, Yamamoto M, et al. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT. Exp Hematol. 2008;36(2):181-192.
53. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 2003;374(Pt 1):1-20.
54. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene. 2000;19(21):2628-2637.
55. Maritano D, Sugrue ML, Tininini S, et al. The STAT3 isoforms α and β have unique and special functions. Nat Immunol. 2004;5(4):401-409.
56. El Kasmi KC, Holst J, Coffre M, et al. General nature of the STAT3-activated anti-inflammatory response. J Immunol. 2006;177(11): 7880-7888.
57. Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. Curr Rheumatol Rev. 2005;1(2):131-142.
58. Tamai M, Kawakami A, Tanaka F, et al. Significant inhibition of TRAIL-mediated fibroblast-like synovial cell apoptosis by IFN-γ through JAK/STAT pathway by translational regulation. J Lab Clin Med. 2006;147(4):182-190.
59. + effector/memory T cells by upregulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology. 2010;130(3):418-426.
60. Blank VC, Peńa C, Roguin LP. STAT1, STAT3 and p38MAPK are involved in the apoptotic effect induced by a chimeric cyclic interferon-α2b peptide. Exp Cell Res. 2010;316(4):603-614.
61. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005;7(3):100-110.
62. Malemud CJ. Dysfunctional immune-mediated inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. Anti Inflamm Anti Allergy Agents Med Chem. In press 2010.
63. Hutcheson J, Perlman H. Apoptotic regulators and RA. Curr Rheumatol Rev. 2008;4(4):254-258.
64. van de Loo FA, Veenbergen S, van den Berg WB. Targeting growth factors in arthritis: a rational for restoring the IGF-1 response in chondrocytes. Curr Rheumatol Rev. 2008;4(4):266-276.
65. Tallheden T, Dennis JE, Lennon DP, Sjögren-Jansson E, Caplan AI, Lindahl A. Phenotypic plasticity of human articular chondrocytes. J Bone Joint Surg Am. 2003;85-A Suppl 2:93-100.
66. Neumann A, Dennis JE, Aigner J, et al. Tissue engineering of autologous cartilage grafts in three-dimensional in vitro macroaggregate culture system. Tissue Eng. 2004;10(11-12):1695-1706.
67. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. 2006;66(13):6468-6472.
68. Huang C, Yang C, Jiang T, Huang K, Cao J, Qiu Z. Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of pancreatic cancer cells in vitro. J Exp Clin Cancer Res. 2010;29(1):51.
69. de Vos J, Jourdan M, Tarte K, Jasmin C, Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol. 2000;109(4):823-828.
70. Seo IA, Lee HK, Shin YK, et al. Janus kinase 2 inhibitor AG490 inhibits the STAT3 signaling pathway by suppressing protein translation of gp130. Korean J Physiol Pharmacol. 2009;13(4):131-138.
71. Wisler BA, Dennis JE, Malemud CJ. New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/autoimmune disorders. Curr Signal Transduct Ther. In press 2010.
72. Legendre F, Bogdanowicz P, Boumediene K, Pujol J-P. Role of interleukin 6 (IL-6)/IL-6R-induced signal transducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol. 2005;32(7):1307-1316.
73. Hu X, Chen J, Wang L, Ivashkiv LB. Crosstalk between Jak-STAT, Toll-like receptor, and ITAM-dependent pathways in macrophage activation. J Leukoc Biol. 2007;82(2):237-243.
74. Abram CL, Lowell CA. The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE. 2007;2007(377): re2.
75. Chen AT, Prchal JT. JAK2 kinase inhibitors and myeloproliferative disorders. Curr Opin Hematol. 2010;17(2):110-116.
76. McQueen FM, Dalbeth N. Will Jill come tumbling after? The case for a JAK2-type mutation as a prequel to the connective tissue disorders. Med Hypotheses. 2009;73(5):651-654.
77. Smolen JS, Maini RN. Interleukin-6: a new therapeutic target. Arthritis Res Ther. 2006;8 Suppl 2:S5.
78. Crawford M, Moreland L. Interleukin-6 receptor antagonist as therapy for rheumatoid arthritis. Curr Rheumatol Rep. 2007;9(5):393-394.
79. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421.
80. Strobl B, Arulampalam V, Is'harc H, et al. A completely foreign receptor can mediate an interferon-γ response. EMBO J. 2001;20(19): 5431-5442.
81. Leonard WJ, O'Shea JJ. Jaks and STATs: biological implications. Annu Rev Immunol. 1998;16:293-322.
82. Sehgal PB. Paradigm shifts in the cell biology of STAT signaling. Semin Cell Dev Biol. 2008;19(4):329-340.
83. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription of binding to NFκB. Genes Dev. 2007;21(11): 1396-1408.
84. Cheon H, Stark GR. Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes. Proc Natl Acad Sci U S A. 2009;106(23):9373-9378.
85. Malemud CJ. Suppression of autoimmune arthritis by small molecule inhibitors of the JAK/STAT pathway. Pharmaceuticals. 2010;3(5): 1446-1455.
86. Zhang L, Badgwell DB, Bevers JJ 3rd, et al. IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the conserved STAT3 N-domain. Mol Cell Biochem. 2006;288(1-2):179-189.
87. Banninger G, Reich NC. STAT2 nuclear trafficking. J Biol Chem. 2004;279(38):39199-39206.
88. Darnell JE Jr. STATS and gene regulation. Science. 1997;277(5332): 1630-1635.
89. Jaruga B, Hong F, Kim W-H, Gao B. IFN-γ/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1. Am J Physiol Gastrointest Liver Physiol. 2004;287(5):G1044-G1052.
90. Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R. Identification of novel IL-4/Stat6-regulated genes in T lymphocytes. J Immunol. 2003;171(7):3627-3635.
91. Gimeno R, Lee CK, Schindler C, Levy DE. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes. Mol Cell Biol. 2005;25(13):5456-5465.
92. Guo L, Wei G, Zhu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17 and Th1 cells. Proc Natl Acad Sci U S A. 2009;106(32):13463-13468.
93. Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE. Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. J Immunol. 2001;166(12):7276-7281.
94. Kaplan MH. STAT4. A critical regulator of inflammation in vivo. Immunol Res. 2005;31(3):231-242.
95. Akira S. IL-6-regulated transcription factors. Int J Biochem Cell Biol. 1997;29(12):1401-1418.
96. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334(Pt 2):297-314.
97. Hintzen C, Haan C, Tuckermann JP, Heinrich PC, Hermanns HM. Oncostatin-M-induced and constitutive activation of the JAK2/STAT5/CIS pathway suppresses CCL1, but not CCL7 and CCL8, chemokine expression. J Immunol. 2008;181(10):7341-7349.
98. Cvijic H, Bauer K, Löffler D, et al. Co-activator SRC-1 is dispensable for transcriptional control by STAT3. Biochem J. 2009;420(1): 123-132.
99. Andreas K, Häupl T, Lübke C, et al. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
100. + cell lines. Exp Hematol. 2007;35(6):957-966.
101. Legendre F, Dudhia J, Pujol J-P, Bogdanowicz P. JAK/STAT but not ERK1/ERK2 pathway mediates interleukin (IL)-6/soluble IL-6R downregulation of Type II collagen, aggrecan core, and link protein transcription in articular chondrocytes. Association with a down-regulation of SOX9 expression. J Biol Chem. 2003;278(5):2903-2912.
102. Brocke-Heidrich K, Ge B, Cvijic H, et al. BCL3 is induced by IL-6 via Stat3 binding to intronic enhancer HS4 and represses its own transcription. Oncogene. 2006;25(55):7297-7304.
103. Snyder M, Huang XY, Zhang JJ. Identification of novel Stat3 target genes for control of growth and differentiation. J Biol Chem. 2008;283(7):3791-3798.
104. Krona A, Aman P, Orndal C, Josefsson A. Oncostatin M-induced genes in human astrocytoma. Int J Oncol. 2007;31(6):1457-1463.
105. Bourillot PY, Aksoy I, Schreiber V, et al. Novel STAT3 target genes exert distinct roles in the inhibition of mesoderm and endoderm differentiation in cooperation with Nanog. Stem Cells. 2009;27(8): 1760-1771.
106. Seki Y, Yang J, Okamoto M, et al. IL-7/STAT5 cytokine signaling pathway is essential but insufficient for maintenance of naïve CD4 T cell survival in peripheral lymphoid organs. J Immunol. 2007;178(1): 262-270.
107. Benczik M, Gaffen SL. The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes. Immunol Invest. 2004;33(2):109-142.
108. Khaled AR, Li WQ, Huang J. Bax deficiency partially corrects interleukin-7 receptor α deficiency. Immunity. 2002;17(5):561-573.
109. Khaled AR, Durum SK. Death and Baxes: mechanisms of lymphotrophic cytokines. Immunol Rev. 2003;193:48-57.
110. Kim H-R, Hwang K-A, Park S-H, Kang I. IL-7 and IL-15: biology and roles in T cell immunity in health and disease. Crit Rev Immunol. 2008;28(4):325-339.
111. + T cells. J Exp Med. 2006;203(6):1459-1470.
112. Bianchi M, Meng C, Ivashkiv LB. Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc Natl Acad Sci U S A. 2000;97(17):9573-9578.
113. Jahn T, Sindhu S, Gooch S, et al. Direct interaction between Kit and the interleukin-7 receptor. Blood. 2007;110(6):1840-1847.
114. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999;42(5):963-970.
115. Lubberts E, Koenders MI, van den Berg WB. The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7(1):29-37.
116. Koenders MI, Lubberts E, van de Loo FAJ, et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J Immunol. 2006;176(10):6262-6269.
117. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. Immunol Rev. 2008;226:132-146.
118. Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors RORα and RORγ. Immunity. 2008;28(1):29-39.
119. Takatori H, Kanno Y, Chen Z, O'Shea JJ. New complexities in helper T cell fate determination and the implications for autoimmune diseases. Mod Rheumatol. 2008;18(6):533-541.
120. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 cells. Annu Rev Immunol. 2009;27:485-517.
121. reg in the steady state. Int Immunol. 2007;19(6):695-702.
122. de Beaucoudrey L, Puel A, Filipe-Santos O, et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J Exp Med. 2008;205(7):1543-1550.
123. + regulatory T cells control TH17 responses in a Stat3-dependent manner. Science. 2009; 326(5955):986-991.
124. Lee Y-H, Benary M, Baumgrass R, Herzel H. Prediction of regulatory transcription factors in T helper cell differentiation and maintenance. Genome Inform. 2010;22:84-94.
125. Hwang SY, Kim JY, Kim KW, et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6(2):R120-R128.
126. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis M-A, Miossec P. Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes. J Immunol. 2009; 182(5):3112-3120.
127. Lexberg MH, Taubner A, Förster A, et al. Th memory for interleukin-17 expression is stable in vivo. Eur J Immunol. 2008;38(10):2654-2664.
128. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets. 2009;8(1):40-52.
129. Partham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699-5708.
130. Wada Y, Lu R, Zhou D, et al. Selective abrogation of the Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor. Blood. 2007;109(3): 1156-1164.
131. Kim H-R, Cho M-L, Kim K-W, et al. Up-regulation of IL-23p19 expression in rheumatoid arthritis synovial fibroblasts by IL-17 through PI3-kinase, NFκB and p38 MAPK-dependent signaling pathways. Rheumatology (Oxford). 2007;46(1):57-64.
132. Liu FL, Chen CH, Chu SJ, et al. Interleukin (IL)-23p19 expression induced by IL-1β in human fibroblast-synoviocytes with rheumatoid arthritis via active nuclear factor κB and AP-1 dependent pathway. Rheumatology (Oxford). 2007;46(8):1266-1273.
133. Kusaba H, Ghosh P, Derin R, et al. Interleukin-12-induced interferon-γ production by human peripheral blood T cells is regulated by mammalian target of rapamycin (mTOR). J Biol Chem. 2005;280(2):1037-1043.
134. Xu H, Zhang Y, Hua Y, Chen T, Wang H, Wu W. IL-12 p35 silenced dendritic cells modulate immune responses by blocking IL-12 signaling through JAK-STAT pathways in T lymphocytes. Biochem Biophys Res Commun. 2007;353(3):812-816.
135. Lund R, Chen Z, Scheinin J, Lahesmaa R. Early target genes of IL-12 and STAT4 signaling in Th cells. J Immunol. 2004;172(11): 6775-6782.
136. Kageyama Y, Ichikawa T, Nagafusa T, Torikai E, Shimazu M, Nagano A. Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3α in patients with rheumatoid arthritis. Rheumatol Int. 2007;28(2):137-143.
137. Sozzani S, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity. 2010;43(3):196-203.
138. Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: insights into the pathogenesis of inflammatory arthritis. Immunol Rev. 2010; 233(1):79-96.
139. Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007;89(6-7):729-734.
140. Dong J, Wang QX, Zhou CY, Ma XF, Zhang YC. Activation of STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus. 2007;16(2):101-109.
141. Rönnblom L, Elkon KB. Cytokines as therapeutic targets in SLE. Nat Rev Rheumatol. 2010;6(6):339-347.
142. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome: potential therapeutic targets. Ann Rheum Dis. 2010;69(6): 945-948.
143. Christova R, Jones T, Wu PJ, et al. P-STAT1 mediates higher-order chromatin remodeling of the human MHC in response to IFNγ. J Cell Sci. 2007;120(Pt 18):3262-3270.
144. Vogl C, Flatt T, Fuhrmann B, et al. Transcriptome analysis reveals a major impact of JAK protein tyrosine kinase 2 (Tyk2) on the expression of interferon-responsive and metabolic genes. BMC Genomics. 2010;11:199.
145. Watling D, Carmo CR, Kerr IM, Costo-Pereira AP. Multiple kinases in the interferon-γ response. Proc Natl Acad Sci U S A. 2008;105(16): 6051-6056.
146. Joshi S, Kaur S, Kroczynska B, Platanias LC. Mechanisms of mRNA translation of the interferon stimulated genes. Cytokine. 2010;52 (1-2):123-127.
147. Tsuno T, Mejido J, Zhao T, Schmeisser H, Morrow A, Zoon KC. IRF9 is a key factor for eliciting the anti-proliferative activity of IFN-α. J Immunother. 2009;32(8):803-816.
148. Kaur S, Uddin S, Platanias LC. The PI3' kinase pathway in interferon signaling. J Interferon Cytokine Res. 2005;25(12):780-787.
149. Kaur S, Sassano A, Dolniak B, et al. Role of the Akt pathway in mRNA translation of interferon-stimulated genes. Proc Natl Acad Sci U S A. 2008;105(12):4808-4813.
150. Kaur S, Katsoulidis E, Platanias LC. Akt and mRNA translation by interferons. Cell Cycle. 2008;7(14):2112-2116.
151. Kaur S, Sassano A, Joseph AM, et al. Dual regulatory roles of phosphatidylinositol-3-kinase in IFN-signaling. J Immunol. 2008; 181(10):7316-7323.
152. Andreas K, Lübke C, Häupl T, et al. Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther. 2008;10(1):R9.
153. Waldburger J-M, Firestein GS. Signaling pathways in rheumatoid arthritis. In: Tak P-P, editor. Progress in Inflammation Research. Basel, Switzerland: Birkhäuser; 2009:155-180.
154. Lee HM, Mima T, Sugino H, et al. Interactions among type I and type II interferon, tumor necrosis factor, and β-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(1):R1.
155. Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev. 2009;8(5):379-383.
156. Sweeney SE, Kimbler TB, Firestein GS. Synoviocyte innate immune responses. II. Pivotal role of IFN regulatory factor 3. J Immunol. 2010;184(12):7162-7168.
157. Österlund PI, Pietilä TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes. J Immunol. 2007;179(6):3434-3442.
158. Kotenko SV, Pestka S. Jak-Stat signal transduction pathway through the eyes of cytokine class II receptor complexes. Oncogene. 2000;19(21):2557-2565.
159. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of anti-inflammatory effects of IL-10 in human macrophages. J Immunol. 2004;172(1): 567-576.
160. Wang M, Liang P. Interleukin-24 and its receptors. Immunology. 2005;114(2):166-170.
161. Trivella DB, Ferreira-Júnior JR, Dumoutier L, Renauld JC, Polikarpov I. Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci. 2010;67(17):2909-2935.
162. Wolk K, Witte E, Witte K, Warszawska K, Sabat R. Biology of interleukin-22. Semin Immunopathol. 2010;32(1):17-31.
163. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol. 2003;21:713-758.
164. Mowen KA, Glimcher LM. Signaling pathways in Th2 development. Immunol Rev. 2004;202:203-222.
165. Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and IL4 locus susceptibility. Annu Rev Immunol. 2006;24: 607-656.
166. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORγ t directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121-1133.
167. Nakayama T, Kimura MY. Memory Th1/Th2 cell generation controlled by Schnurri-2. In: Zanetti M, Schoenberger SP, editors. Memory T Cells. New York, NY: Springer Science; 2010:1-9.
168. Hermann J, Gruber S, Neufeld JB, et al. IL10R1 loss-of-function alleles in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Rheumatol. 2009;27(4):603-608.
169. Riley JK, Takeda K, Akira S, Schreiber RD. Interleukin-10 receptor signaling through the JAK-STAT pathway. Requirement for two distinct receptor-derived signals for anti-inflammatory action. J Biol Chem. 1999;274(23):16513-16521.
170. Ahmed ST, Ivashkiv LB. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol. 2000; 165(9):5227-5237.
171. Herrero C, Hu X, Li WP, et al. Reprogramming of IL-10 activity and signaling by IFN-γ. J Immunol. 2003;171(10):5034-5041.
172. Ji JD, Tassiulas I, Park-Min KH, et al. Inhibition of interleukin 10 signaling after Fc receptor ligation and during rheumatoid arthritis. J Exp Med. 2003;197(11):1573-1583.
173. van Roon J, Wijngaarden S, Lafeber FP, Damen C, van de Winkel J, Bijlsma JW. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fc γ receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol. 2003;30(4): 648-651.
174. Kalliolias GD, Ivashkiv LB. IL-27 activates human monocytes via STAT1 and suppresses IL-10 production but the inflammatory functions of IL-27 are abrogated by TLRs and p38. J Immunol. 2008;180(9):6325-6333.
175. Shahrara S, Huang Q, Mandelin AM 2nd, Pope RM. TH-17 cells in rheumatoid arthritis. Arthritis Res Ther. 2008;10(4):R93.
176. Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connection maps. Science. 2003;300(5625):1527-1528.
177. Ratthé C, Pelletier M, Chiasson S, Girard D. Molecular mechanisms involved in interleukin-4-induced human neutrophils: expression and regulation of suppressor of cytokine signaling. J Leukoc Biol. 2007;81(5):1287-1296.
178. Wang IM, Lin H, Goldman SJ, Kobayashi M. STAT-1 is activated by IL-4 and IL-13 in multiple cell types. Mol Immunol. 2004;41(9): 873-884.
179. Morita Y, Yamamura M, Kawashima M, et al. Differential in vitro effects of IL-4, IL-10, and IL-13 on proinflammatory cytokine production and fibroblast proliferation in rheumatoid synovium. Rheumatol Int. 2001;20(2):49-54.
180. Woods JM, Katschke KJ, Volin MV, et al. IL-4 adenoviral gene therapy reduces inflammation, proinflammatory cytokines, vascularization, and bony destruction in rat adjuvant-induced arthritis. J Immunol. 2001;166(2):1214-1222.
181. Nabbe KC, van Lent PL, Holthuysen AE, et al. Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation. Arthritis Res Ther. 2005;7(2):R392-R401.
182. Relic B, Guicheux J, Mezin F, et al. IL-4 and IL-13, but not IL-10, protect human synoviocytes from apoptosis. J Immunol. 2001;166(4): 2775-2782.
183. Tokayer A, Carsons SE, Chokshi B, Santiago-Schwarz F. High levels of interleukin-13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity. J Rheumatol. 2002;29(3):454-461.
184. Woo KM, Kim HM, Ko JS. Macrophage colony-stimulating factor promotes the survival of osteoclast precursors by up-regulating Bcl-X(L). Exp Mol Med. 2002;34(5):340-346.
185. Rumore-Maton B, Elf J, Belkin N, et al. M-CSF and GM-CSF regulation of STAT5 activation and DNA binding in myeloid cell differentiation is disrupted in nonobese diabetic mice. Clin Dev Immunol. 2008;2008:769795.
186. Haas CS, Amin MA, Allen BB, et al. Inhibition of angiogenesis by interleukin-4 therapy in rat adjuvant-induced arthritis. Arthritis Rheum. 2006;54(8):2402-2414.
187. Haas CS, Amin MA, Ruth JH, et al. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum. 2007;56(8):2535-2548.
188. Ruth JH, Haas CS, Park CC, et al. CXCL16-mediated cell recruitment to rheumatoid arthritis synovial tissue and murine lymph nodes is dependent on the MAPK pathway. Arthritis Rheum. 2006;54(3): 765-778.
189. + regulatory T cells: CD25 and IL-2. Front Biosci. 2006;11:921-927.
190. Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19(21):2566-2576.
191. Murawski MR, Litherland SA, Clare-Salzler MJ, Davoodi-Semiromi A. Upregulation of Foxp3 expression in mouse and human Treg is IL-2/STAT5 dependent: implications for the NOD STAT5B mutation in diabetes pathogenesis. Ann N Y Acad Sci. 2006;1079:198-204.
192. + cells in steady-state homeostasis. J Immunol. 2006;177(4):2216-2223.
193. + Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest. 2009;119(3):551-564.
194. Streitholt S, Maurer B, Peters MA, Pap T, Gay S. Epigenetic modifications in rheumatoid arthritis. Arthritis Res Ther. 2008;10(5):219.
195. Karouzakis E, Gay RE, Gay S, Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol. 2009;5(5):266-272.
196. Brooks WH, Le Dantec C, Pers JO, Youinou P, Renaudineau Y. Epigenetics and autoimmunity. J Autoimmun. 2010;34(3): J207-J219.
197. Li WX. Canonical and non-canonical JAK-STAT signaling. Trends Cell Biol. 2008;18(11):545-551.
198. Shin HJ, Park HY, Jeong SJ, et al. STAT4 expression in human T cells is regulated by DNA methylation but not by promoter polymorphism. J Immunol. 2005;175(11):7143-7150.
199. Kim EG, Shin HJ, Lee CG, et al. DNA methylation and not allelic variation regulates STAT6 expression in human T cells. Clin Exp Med. 2010;10(3):143-152.
200. Shi S, Calhoun HC, Xia F, Li J, Le L, Li WX. JAK signaling globally counteracts heterochromatin gene silencing. Nat Genet. 2006; 38(9):1071-1076.
201. Nile CJ, Read AC, Akil M, Duff GW, Wilson AG. Methylation status of a single CpG site in the IL6 promoter is related to IL6 messenger RNA levels and rheumatoid arthritis. Arthritis Rheum. 2008;58(9): 2686-2693.
202. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol. 2009;5(10): 549-553.
203. Genovese MC, van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, doubleblind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929-939.
204. Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/ IL-23 antibody for the potential treatment of autoimmune diseases. Curr Opin Investig Drugs. 2008;9(5):515-522.
205. Lima XT, Abuabara K, Kimball AB, Lima HC. Briakinumab. Expert Opin Biol Ther. 2009;9(8):1107-1113.
206. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann N Y Acad Sci. 2009;1182:97-110.
207. Hartgring SAY, van Roon JAG, Wijk MWV, et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum. 2009;60(9):2595-2605.
208. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterization of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis. 2010 Jun 15. [Epub ahead of print] PMID: 20551157.
209. O'Shea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov. 2004;3(7):555-564.
210. Feely MG. New and emerging therapies for the treatment of rheumatoid arthritis. Open Access Rheumatol Res Rev. 2010;2:35-43.
211. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895-1905.
212. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2010;69(2):413-416.
213. Kim BH, Oh SR, Yin CH, et al. MS-1020 is a novel small molecule that selectively inhibits JAK3 activity. Br J Haematol. 2010;148(1): 132-143.
214. Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/JAK2 inhibitor ICNB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109-3117.
215. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol. 2010;184(9):5298-5307.
216. Messerschmitt PJ, Rettew AN, Brookover RE, Garcia RM, Getty PJ, Greenfield EM. Specific tyrosine kinase inhibitors regulate human osteosarcoma cells in vitro. Clin Orthop Relat Res. 2008;466(9):2168-2175.
217. Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010;115(25):5232-5240.
218. Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617Finduced polycythemia vera. Cancer Cell. 2008;13(4):311-320.
219. Geron I, Abrahamsson AE, Barroga CF, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008;13(4):321-330.
220. Sun J, Blaskovich MA, Jove R, et al. Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene. 2005;24(20): 3236-3245.
221. Horiguchi A, Asano T, Kuroda K, et al. STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102(11):1592-1599.
222. Zhang L, Alizadeh D, van Handel M, Kortylewski M, Yu H, Badie B. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice. Glia. 2009;57(13):1458-1467.
223. Spagnoli A, Torello M, Nagalla SR, et al. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J Biol Chem. 2002;277(21):18860-18867.
224. Shipley JM, Waxman DJ. Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) α and PPARγ. Mol Pharmacol. 2003;64(2):355-364.
225. Böhm C, Hayer S, Kilian A, et al. The α-isoform of p38 kinase MAPK specifically regulates arthritic bone loss. J Immunol. 2009;183(9): 5938-5947.
226. Genovese MC. Inhibition of p38: has the fat lady sung? Arthritis Rheum. 2009;60(2):317-320.
227. Hammaker D, Firestein GS. Go upstream, young man: lessons learned from the p38 saga. Ann Rheum Dis. 2010;69 Suppl 1:i77-i82.